Qingzhi Intelligence Completes Tens-of-Millions RMB Angel Round Led by TusStar Ventures to Build an AI-Driven Surgical Healthcare Platform

VCBeat has learned that in April 2025, a technology company focusing on AI medical equipment and digital surgery platformsChangzhou Qingzhi Intelligent Technology Co., Ltd. (hereinafter referred to as “Qingzhi Intelligence”）Announced the completion of an angel round financing worth tens of millions of RMB. This round of financing was led byTusStar Venture CapitalLead investment; the funds will be primarily allocated to the promotion of digital therapeutics devices, R&D of prototypes for embodied medical robots, training of AI data engines, and channel expansion.

Qingzhi Intelligence was incubated as a project by the Department of Automation at Tsinghua University. With AI technology at its core, the company is committed to enhancing the efficiency of surgical medical services, reducing service costs, and expanding the scale of healthcare delivery.The company’s flagship product, the “Digital Exercise Therapy Monitor,” has been deployed in collaboration with multiple leading medical institutions across China. While ensuring clinical efficacy, it has reduced per-item healthcare service costs by nearly 60% and expanded patient service capacity by 300%.

Qingzhi Intelligence deeply integrates its AI Agents, independently trained on high-quality medical data, with digital embodied equipment. It provides systematic solutions to address efficiency bottlenecks, cost pressures, and data management challenges in hospital surgical diagnosis and treatment, effectively helping healthcare institutions improve service efficiency, reduce operational costs, and rapidly expand the scale of patient services.

To date, the company’s products have cumulatively provided 3.5 million minutes (58,000 hours) of patient treatment services, accumulating high-quality medical data and 8.7 billion tokens of AI training corpus, thereby establishing an efficient commercial closed loop spanning data collection, AI training, and equipment application.

Qingzhi Intelligence is developing the “Medical Embodied Robot,” positioned as a comprehensive surgical assistance platform. Driven by intelligent agents, collaborative robotic arms, multimodal sensors, and natural language processing systems, it can be applied to outpatient triage, inpatient diagnostic and therapeutic assistance, physical therapy, and nursing management, thereby promoting the automation and scalability of healthcare services. The prototype is expected to be launched in September 2025, with full commercialization achieved in 2026.

Under the policy backdrop of DRG and centralized procurement, the bottleneck for medical institutions in delivering patient care services lies in the inversion between hospitals' comprehensive service costs and existing fee schedules.

In this context, leveraging AI-integrated embodied devices to help healthcare institutions enhance clinical outcomes, reduce overall costs, and expand service capacity is not only an intrinsic imperative for the nation and hospitals but also a strategic focus for medical technology and equipment enterprises.

In November 2024, the National Healthcare Security Administration explicitly supported the inclusion of AI-assisted diagnosis and treatment in reimbursable medical services. With clear policy signals and well-defined industrial guidance for technological development, the integrated orthopedic treatment and rehabilitation sector alone is projected to achieve an annual market size exceeding RMB 40 billion, creating significant growth opportunities for Qingzhi Intelligence.

Liu Bo, General Manager of TusStar Venture CapitalIt indicates that, against the backdrop of deepening reforms in medical insurance payment methods such as DRG (Diagnosis-Related Groups) and DIP (Big Data Diagnosis-Intervention Packet), digital therapeutics for rehabilitation has become a key breakthrough in empowering the healthcare services market, thanks to its precision and accessibility. Leveraging its core strength in integrating medicine with engineering, Qingzhi Intelligence has demonstrated significant industry leadership in the field of accelerated recovery for digital orthopedics. By employing AI technologies to overcome traditional constraints on medical resources, it enables high-quality rehabilitation services to benefit a broader patient population through standardized and intelligent approaches, while simultaneously enhancing medical quality and optimizing the efficiency of medical insurance fund utilization.

Qingzhi Intelligence, leveraging the top-tier research team from the Department of Automation at Tsinghua University and deep clinical collaborations with leading orthopedic hospitals across China, has established the nation’s first fee-for-service system for AI-assisted orthopedic diagnosis and secured unrestricted recognition of its clinical technology, thereby creating high entry barriers. Its independently developed AI engine addresses the “black box” issue of large medical models through a “multi-agent architecture + traceable knowledge graph.” Combined with hardware designed for disposable use, this solution has achieved a closed-loop commercialization model at leading institutions such as Shanghai Sixth People’s Hospital and Changzheng Hospital. This validates its essential value in “cost reduction and efficiency enhancement plus health insurance compatibility,” significantly lowering treatment costs, breaking through traditional labor constraints in rehabilitation, and enabling exponential growth in hospital treatment capacity. Furthermore, Qingzhi Intelligence’s flexible, scalable disposable-business model and clear plans for expanding reimbursable billing codes position it to capture a leading share in the hundred-billion-yuan orthopedic rehabilitation market.

TusStar Venture Capital led this round of investment, recognizing the company’s quadruple synergy across “technology, clinical practice, policy, and commercialization.” The team combines academic authority with market-driven execution capabilities. As medical insurance payment standards become deeply integrated with the reimbursement framework for digital therapeutics, Qingzhi’s solution—featuring an “AI-powered orthopedic rehabilitation engine + intelligent hardware terminals”—will continue to facilitate the decentralization of high-quality medical resources. With ongoing expansion of reimbursement qualifications and advancement in the clinical translation of embodied robots for rehabilitation, the company promises significant growth potential.